BIOA Investor Alert: A securities fraud class action lawsuit has been filed against BioAge Labs, Inc. (BIOA)
RADNOR, PA – January 15, 2025 (NEWMEDIAWIRE) – The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that against BioAge Labs, Inc. (BioAge) securities class action lawsuit filed. (NASDAQ: BIOA) on behalf of those who purchased stock pursuant to and/or traceable to BioAge’s registration statement for its initial public offering (IPO) held on or about September 26, 2024 (the Class Period). The deadline for the chief prosecutor is March 10, 2025.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you have suffered BioAge losses, you can CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/bioage-labs-inc?utm_source=PR&utm_medium=link&utm_campaign=bioa&mktm=r
You may also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or emailing info@ktmc.com.
ALLEGED MISCONDUCT OF THE ACCUSED:
The complaint alleges that in the registration statement and prospectus issued in connection with BioAges’ IPO, the defendants made false and/or misleading statements and/or failed to disclose information relevant to investors regarding the BioAges STRIDES Phase 2 trial of azelaprag. Specifically, Defendants misrepresented and/or failed to disclose: (1) the possibility of hepatic transaminitis in any of their previous STRIDES phase 1 clinical trials and various preclinical toxicology studies; (2) that there were no safety issues and that BioAge expected the best results and met its primary endpoints with respect to its STRIDES clinical trial; and (3) as a result, the defendant’s statements about the company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
PROCEDURE OF THE CHIEF PROSECUTOR:
BioAge investors may, no later than March 10, 2025, seek to be appointed as lead plaintiff, class representative through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. The lead plaintiff is the representative party that acts on behalf of all class members in the conduct of the litigation. The lead plaintiff is usually an investor or a small group of investors who have the greatest financial interest and who are also appropriate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and those attorneys, if approved by the court, are lead or class counsel. The decision whether or not to be the lead plaintiff does not affect your ability to participate in the recovery.
Kessler Topaz Meltzer & Check, LLP encourages BioAge investors who have suffered significant losses to contact the company directly for more information.
CLICK HERE TO APPLY FOR A CASE OR VISIT: https://www.ktmc.com/new-cases/bioage-labs-inc?utm_source=PR&utm_medium=link&utm_campaign=bioa&mktm=r
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP litigates class actions in state and federal courts nationwide and around the world. The company has built a global reputation for excellence and has recovered billions of dollars from victims of fraud and other corporate wrongdoing. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by companies and fiduciaries. The appeal in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP, visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
info@ktmc.com
May be considered solicitor advertising in certain jurisdictions. Past results do not guarantee future results.
See the original release at www.newmediawire.com
Copyright 2025 JCN Newswire. All rights reserved.
